Clinical Trial Update: Treatment Safety and Efficacy of Pro-ocular™ 1% for Chronic Ocular Graft Following Allogeneic HSCT. [Phase 2]

View source ↗

Summary

A Phase 2 trial assessing the safety and efficacy of Pro-ocular 1% for chronic ocular graft-versus-host disease has completed and results have been posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Graft-versus-host Disease

Drugs mentioned

• Pro-ocular 1%

Snippet

Sponsor: Glia, LLC | Conditions: Chronic Ocular Graft-versus-host Disease | Phase 2 | Status: COMPLETED | Results posted: 2025-05-06